EX-99.2 3 d794204dex992.htm EX-99.2 EX-99.2
Filippo G. De Braud
1
, Lorenzo Pilla
1
, Monica Niger
1
, Silvia
Damian
1
, Benedetta Bardazza
1
, Antonia Martinetti
1
, Giuseppe
Pelosi
1
, Giovanna Marrapese
2
, Laura Palmeri
2
, Giulio Cerea
2
,
Emanuele Valtorta
2
, Silvio Veronese
2
, Andrea Sartore-Bianchi
2
,
Elena Ardini
3
, Marcella Martignoni
4
, Antonella Isacchi
3
, Arturo
Galvani
3
, David Luo
5
, Litain Yeh
5
, Adrian Senderowicz
5
,
and Salvatore Siena
2
1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;
2
Ospedale Niguarda Ca' Granda, Milan, Italy;
3
Nerviano Medical Sciences, Nerviano, Italy;
4
CLInical Organization for Strategies & Solutions (CLIOSS), NMS
Group, Nerviano, Italy;
5
Ignyta, Inc., San Diego, CA
Phase 1 Open Label, Dose Escalation
Study of RXDX-101, an Oral Pan-Trk,
ROS1, and ALK Inhibitor, in Patients with
Advanced Solid Tumors with Relevant
Molecular Alterations
Exhibit 99.2


Abstract
2
Background:  RXDX-101 is a small molecule inhibitor of TrkA, TrkB, TrkC, ROS1 and ALK, with high
potency and selectivity. RXDX-101 demonstrated potent pharmacological activity in preclinical studies
and is potentially first-in-class against the Trk family of kinases. This study aims to determine MTD, PK,
PD and anti-tumor activity in patients with advanced cancer and applicable molecular alterations.
Methods:  Phase 1 dose escalation in patients with advanced solid tumors. RXDX-101 was dosed orally
once/day in a 4 day on, 3 day off schedule for 3 weeks, followed
by a 7 day rest period, in continuous
28-day cycles (Schedule A); once/day in continuous 28-day cycles (Schedule B); and once/day in a 4
day on, 3 day off schedule without interruption in continuous 28-day cycles (Schedule C). Minimum of 3
patients were enrolled at each dose level. Endpoints include safety, PK, and tumor response by RECIST.
Results:
19
patients
have
been
treated
at
6
dose
levels
(100,
200,
400,
800,1200
and
1600
mg/m
)
in
Schedule
A;
3
patients
at
one
dose
level
(200
mg/m
)
in
Schedule
B;
and
3
patients
at
one
dose
level
(400
mg/m
)
in
Schedule C.  RXDX-101 has been well tolerated to date; the MTD has not been reached.  No DLT has
been seen at any dose level in any dosing schedule. The most common AEs (mainly grade 1-2)
considered possibly treatment-related included paresthesia, nausea, diarrhea, asthenia, myalgia,
vomiting, arthralgia, and dysgeusia.  There was one possibly treatment-related grade 3 AE of asthenia.
No treatment-related serious adverse events have been reported.
A patient with colorectal carcinoma (TrkA+) had a PR and progressed after cycle 4.  One patient with
NSCLC (ROS1+) has achieved CR, and three patients with NSCLC (2 ROS1+; 1 ALK+) have achieved
PRs, and all remain on treatment. An additional patient with neuroblastoma (ALK+) has a PR and is
currently in cycle 21. Two patients have had prolonged stabilization of their disease: a patient with
NSCLC (ALK+) in cycle 19 who remains on treatment and a patient with pancreatic cancer (ROS1+) who
progressed in cycle 11.
PK analysis shows maximum concentrations of RXDX-101 were generally achieved within 2 to 4 hours
following dosing and exposure increased in an approximate dose proportional manner up to doses of
800
mg/m
with
minimal
accumulation
following
multiple
doses.
Mean
plasma
half-life
was
17
to
44
hours and steady state reached within 4 days.
Conclusions: RXDX-101 intermittent and continuous dosing schedules have been well tolerated in
patients with advanced solid tumors.  Early responses in patients with 3 different relevant molecular
alterations are promising.  A global phase I/II trial was recently initiated.
2
2
2
2


Introduction
RXDX-101 is a potent, selective, orally available inhibitor of the tyrosine kinases TrkA
(coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene
NTRK3),
ROS1
(coded
by
the
gene
ROS1),
and
ALK
(coded
by
the
gene
ALK).
Molecular
alterations to these targets are present in several different tumor types, including non-small
cell lung cancer (NSCLC), colorectal cancer (CRC), papillary thyroid cancer, pancreatic
cancer, and neuroblastoma, among others.
Potent in vitro and in vivo antitumor effects have been observed
in several TRK, ROS1 and
ALK-dependent tumor models. Antitumor effects in the preclinical models were associated
with
apoptosis
and
downstream
signaling
effects,
leading
to
MAPK
and
AKT
modulation.
RXDX-101 is currently being evaluated in ALKA-372-001, a First-in-Human (FIH) study that
began in October 2012 and is being conducted in Italy. ALKA-372-001 is an ongoing,
Phase 1, open-label study evaluating the safety, pharmacokinetics, and antitumor activity of
RXDX-101 in patients with advanced/metastatic solid tumors that harbor a TrkA, ROS1, or
ALK molecular alteration.
RXDX-101 is also being evaluated in RXDX-101-01, a new Phase 1/2a study, also referred
to as STARTRK-1 (Study
Targeting
ALK,
ROS1 and
TRKA/B/C), that was initiated in July
2014 and is being conducted in the U.S. The data presented are from ALKA-372-001 only. 
3


Methods
Patient
population:
Patients
with
locally
advanced
or
metastatic
solid
tumors,
with
TrkA,
ROS1
or
ALK
molecular
alterations
Dosing
schedules
and
cohorts
(see
Table
1):
To
date,
three
different
schedules
of
administration
of
RXDX-101
have been assessed. A total of 26 patients have been enrolled, and 25 dosed in the 3 schedules.
4
Schedule
Cohort
Daily Dose Level
# of Patients Treated
A
1
100 mg/m
3
2
200 mg/m
3
3
400 mg/m
4
4
800 mg/m
3
5
1200 mg/m
3
6
1600 mg/m
3
B
1
200 mg/m
3
C
1
400 mg/m
3
Primary
objectives:
DLT,
MTD,
RP2D
Secondary
objectives:
safety,
PK,
antitumor
activity
by
RECIST
Table 1
Schedule A evaluated ascending oral doses of RXDX-101 once daily (fasted state) in a 4-day on, 3-day off schedule for 3 weeks,
followed by a 7-day rest period, in continuous 28-day cycles. Dose escalation was conducted according to the standard ‘3 + 3’
scheme (see Figure 1a). Enrollment has been completed (n = 19) for Schedule A.
Schedule B is evaluating ascending oral doses of RXDX-101 once daily (fed state) without rest, in continuous 28-day cycles (see
Figure
1b).
Enrollment
is
ongoing
(n
=
3).
Schedule C is evaluating ascending oral doses of RXDX-101 once daily (fed state) in a 4-day on, 3-day off schedule for 4 weeks
without rest, in continuous 28-day cycles (see Figure 1c). Enrollment is ongoing (n = 3).
2
2
2
2
2
2
2
2


Figure 1. Dosing Schedules
5
1
2
3
4
Week
Figure 1a. Schedule A
1
2
3
4
Week
Figure 1c. Schedule C
1
2
3
4
Week
Figure 1b. Schedule B
Dose
Dose
Dose
Break
Break


n = 25
Age, mean (range) years
51 (22-75)
Female, n (%)
15 (60)
Race, %
White
100
Histology, n (%)
NSCLC
Neuroblastoma
CRC
Pancreatic
Leiomyosarcoma
GBM
16 (64)
4 (16)
2 (8)
1  (4)
1  (4)
1 (4)
Performance status (ECOG)
0
1
2
12
12
1
Prior systemic therapy
1
2   
3 or more
3
5
17
Table 2. Demographics and Baseline Characteristics
6


Primary Diagnosis
Molecular Alteration
N
NSCLC
ALK       rearrangement
ROS1    6 rearrangements
1 deletion
1 copy number gain
8*
8
CRC
TrkA      rearrangement
ROS1     deletion
1
1
Neuroblastoma
ALK        mutation
ROS1     rearrangement
TrkA      overexpression
2
1
1
Glioblastoma
None**
1
Pancreatic
ROS1     deletion
1
Leiomyosarcoma
ALK        deletion
1
Table 3. Histology and Molecular Alteration
7
* 7 had prior treatment w/ crizotinib
** Patient had false positive TrkA IHC result


Results
A total of 25 patients have been treated in ALKA-372-001 (see Table 1)
Schedule
A
was
terminated
at
1600
mg/m
/day
due
to
a
plateau
of
RXDX-101
exposure
and the data were presented previously (ASCO 2014 oral presentation)
RXDX-101 has been well tolerated in all dosing schedules tested thus far (both on an
intermittent and daily continuous basis). Most AEs
<
Grade 2 (see Table 4)
Only
1
possibly
drug-related
Grade
>3
AE
has
been
observed:
asthenia
(1200
mg/m
,
Schedule
A),
that
subsided
with
dose
reduction
to
800
mg/m
/day
No DLTs or drug-related SAEs have been reported in any dosing schedule 
1 complete response has been observed in this trial (see Figure 2)
5 partial responses have been observed in this trial (see Figures 2, 3, 4 and 5)
2 prolonged stable diseases have been observed: a patient with NSCLC with brain
metastases (18 cycles) and a patient with pancreatic adenocarcinoma (11 cycles)
Exposure to RXDX-101 increased in an approximate dose proportional manner up to
doses of 800 mg/m2 with mean plasma half-life of 17 to 44 hours (see Figure 6)
Responders tend to have higher exposure than non-responders throughout the entire
dosing cycle in Schedule A (see Figure 7)
8
2
2
2


Results (cont’d)
9
Complete Response
NSCLC patient (N=1)
Partial Responses
-
46 year old female, ROS1 rearrangement, s/p 2 cycles of chemotherapy, achieved CR after 2 cycles of RXDX-101 (400
mg/m2/day, Schedule C). CR is ongoing (pt currently in cycle 2).
-
63 year old female with metastatic adenocarcinoma, ALK rearrangement, s/p 4 cycles of chemotherapy, crizotinib,
achieved PR after 4 cycles of RXDX-101 (1200 mg/m²/day, Schedule A). PR is ongoing (pt currently in cycle 11) (see
Figure 3).
-
44 year old female with metastatic disease (CNS metastases), ROS1 rearrangement, s/p 3 cycles of chemotherapy,
erlotinib, s/p surgery/XRT to brain, achieved PR after 2 cycles of RXDX-101 (1200 mg/m²/day, Schedule A). PR is ongoing
(pt currently in cycle 10).
-
63 year old male, ROS1 rearrangement, s/p 3 cycles of chemotherapy, achieved PR after 1 cycle of RXDX-101 (400
mg/m²/day, Schedule C). PR is ongoing (pt currently in cycle 3) (see Figure 4).
-
75
year
old
female
with
metastatic
CRC,
TrkA
rearrangement,
s/p
3
cycles
of
chemotherapy,
cetuximab,
achieved
PR
after 1 cycle of RXDX-101 (1600 mg/m², Schedule A). PR lasted for 4 cycles before PD (see Figure 5).
-
22 year old female with metastatic NB, ALK mutation, s/p 4 cycles of chemotherapy, achieved PR after 12 cycles of
RXDX-101 (started at 200 mg/m²/day and had subsequent dose escalations to1200 mg/m²/day, Schedule A). PR is
ongoing (pt currently in cycle 21).
NSCLC patients (N=3)
CRC (N=1):
Neuroblastoma (N=1)


Adverse Event
G1 (%)
G2 (%)
Total (%)**
Nausea
14 (56)
2 (8)
16 (64)
Paresthesia
14 (56)
0 (0)
14 (56)
Asthenia
9 (36)
3 (12)
13 (52)
Vomiting
7 (28)
2 (8)
9 (36)
Diarrhea
6 (24)
2 (8)
8 (32)
Myalgia
6 (24)
1 (4)
7 (28)
Abdominal pain
4 (16)
2 (8)
6 (24)
Back Pain
5 (20)
1 (4)
6 (24)
Arthralgia
3 (12)
3 (12)
6 (24)
Headache
6 (24)
0 (0)
6 (24)
Dyspnea
2 (8)
1 (4)
6 (24)
Pyrexia
6 (24)
0 (0)
6 (24)
Dysgeusia
6 (24)
0 (0)
6 (24)
Cough
4 (16)
1 (4)
5 (20)
* Frequency >
20%, all dosing schedules
Table 4. Most Common* Adverse Events (n=25)
** Total includes one possibly drug-related G3 asthenia AE (4%) and three unrelated G3 dyspnea AEs (12%)
-
Overall, one G4 (increased lipase) and one G5 (respiratory failure) AE have been
reported (both unrelated)


Figure 2. Clinical Antitumor Activity in Each of
TrkA, ROS1 and ALK Patients
Tumor type
(Alteration)
Dose
(mg/m²)
Treatment Cycles / Months
Best
Response
2
4
6
8
10
12
14
16
18
20
22
24
Neuroblastoma
(ALK)
200  
400
800  
1200
PR
NSCLC
(ALK)
200 
400
800
SD
Pancreatic
(ROS1)
400
800
SD
NSCLC
(ALK)
1200
800
PR
NSCLC
(ROS1)
1200
PR
CRC
(TrkA)
1600
PR
NSCLC
(ROS1)
400**
PR
NSCLC
(ROS1)
400***
CR*
PD at C11
PD at C4
11
*  Unconfirmed
**
All
PRs
were
in
Schedule
A
except
1
patient
with
ROS1+
NSCLC
in
Schedule
C
***  CR was in Schedule C
Timing of PR
Timing of CR


Figure 3. Patient 15, NSCLC ALK+
Schedule A, 1200 mg/m²
Baseline, 11/2013
Week 8, 1/2014
Week 20, 5/2014
12
2


Baseline, 7/2014
Week 4, 8/2014
Figure 4. Patient 22, NSCLC ROS1+
Schedule C, 400 mg/m²
13
2


Baseline, 3/2014
Week 4, 4/2014
Figure 5. Patient 20, CRC TrkA+
Schedule A, 1600 mg/m²
14
2


•
Exposure to RXDX-
101 increased in an
approximate dose
proportional manner
up to doses of 800
mg/m
•
Mean plasma half-life
was 17 –
44 hours
3
3
4
3
3
3
n
Figure 6.
RXDX-101 Schedule A Steady State PK Profile
15
100 mg/m
200 mg/m
400 mg/m
800 mg/m
1200 mg/m
1600 mg/m
2
2
2
2
2
2
100
1000
10000
Time (Day)
4
5
2


Figure 7. Responders Tend to Have Higher Exposure than
Non-Responders Throughout the Entire Dosing Cycle
16
Note:
Analysis
includes
patients
in
the
800,
1200
and
1600
mg/m
cohorts;
mean
is
represented
by
square,
and
standard error of the mean is represented by error bars
1
2
3
4
Week
Non-responders
(n = 6)
Responders
(n = 3)
Day 18, T
96h
RXDX-101 Exposure Levels of
Responders and Non-Responders
Intermittent Dosing Schedule (Schedule A, fasted)
(4 days on, 3 days off, 1 week break)
The following may further increase
RXDX-101 exposure:
Additional PK Optimization
Dose
Break
Fed (vs. fasted) state
New formulation
Continuous dosing schedules
without breaks
•
•
•
2


Conclusions and Future Directions
A total of 25 patients have been evaluated across 3 different dosing schedules in this First-in-Human trial of RXDX-
101
There was 1 complete response and 5 partial responses across multiple tumor types (NSCLC, CRC, and
neuroblastoma) in patients with TrkA, ROS1, and ALK molecular alterations; three of them were prolonged (> 9
cycles) and two of them are too early to determine. There were also two patients with prolonged stable disease:
NSCLC with brain metastases (18 cycles) and pancreatic adenocarcinoma (11 cycles)
RXDX-101 has been well tolerated in all dosing schedules tested to date, including intermittent and daily
continuous administration
-
Most common AEs (mainly grade 1-2) considered possibly drug-related were paresthesia, nausea, diarrhea,
asthenia, myalgia, vomiting, arthralgia, and dysgeusia
-
Only 1 possibly drug-related Grade
>3 AE has been observed: asthenia (Grade 3 in one patient)
-
No DLTs or drug-related SAEs have been reported in any dosing schedule
In preliminary PK analysis (day 18, T
96h
), it appears that responders have higher RXDX-101 median Cmin
concentrations vs. non-responders
STARTRK-1, a global Phase 1/2a trial, is ongoing
STARTRK-2
study
will
begin
as
soon
as
RP2D
is
established
in
these
Phase
1
studies
Ignyta is developing a proprietary companion diagnostic for patient selection into RXDX-101 clinical studies
17